Tumor Board Tuesday shared a post on X:
“Fresh off a recent FDA approval of a new agent for neuroendocrine tumors (NETs).
Join us on Tuesday, 04-01-25 at 8 pm ET as Rachel Riechelmann and Guilherme Rossato treatment options for a patient with a pancreatic NET.
RT and bring others into the discussion.”
